Stockscreener 앱 받기
73.55
1.37%
-1.02
시간 외 거래:
73.82
0.27
+0.37%
전일 마감가:
$74.57
열려 있는:
$73.47
하루 거래량:
4.93M
Relative Volume:
1.05
시가총액:
$228.10B
수익:
$56.50B
순이익/손실:
$8.30B
주가수익비율:
27.70
EPS:
2.655
순현금흐름:
$8.18B
1주 성능:
-0.54%
1개월 성능:
+5.04%
6개월 성능:
+2.17%
1년 성능:
-10.14%
1일 변동 폭
$73.11
$73.90
1주일 범위
$73.11
$75.10
52주 변동 폭
$61.24
$87.67
아스트라제네카 ADR Stock (AZN) Company Profile
명칭
Astrazeneca PLC
전화
44 20 3749 5000
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
73.55 | 228.20B | 56.50B | 8.30B | 8.18B | 2.655 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca’s NeoCOAST-2 Study: A New Frontier in Lung Cancer Treatment - The Globe and Mail
AstraZeneca’s Andexanet Alfa Study: Real-World Insights for Investors - The Globe and Mail
AstraZeneca’s Real-World Study on Koselugo: Key Insights for Investors - The Globe and Mail
AstraZeneca’s Phase II Study on Olaparib in Ovarian Cancer: A Market Perspective - The Globe and Mail
AstraZeneca’s Anifrolumab Study: A Potential Game-Changer in Inflammatory Myopathies - TipRanks
AstraZeneca’s EXCEED Study: Assessing Pancreatic Cancer Risk in Diabetes Treatment - TipRanks
AstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: A Potential Game-Changer for CKD Treatment - TipRanks
AstraZeneca’s Latest NSCLC Study: A Potential Game-Changer? - The Globe and Mail
AstraZeneca’s Promising CAR T-Cell Therapy Study: Key Insights for Investors - TipRanks
AstraZeneca’s Anifrolumab Study: Real-world Insights into SLE Treatment - TipRanks
AstraZeneca’s ARTEMIDE-Lung03 Study: A New Frontier in NSCLC Treatment - TipRanks
AstraZeneca’s PANGEIA-2 Study: Unveiling New Insights in Breast Cancer Mutations - TipRanks
AstraZeneca’s TROPION-Lung05 Study: A New Hope for Advanced NSCLC - TipRanks
AstraZeneca’s New Trial: Exploring AZD8421 for Advanced Cancers - TipRanks
AstraZeneca’s Real-World Study on mCRPC Treatment: Key Insights for Investors - TipRanks
AstraZeneca’s Osimertinib Study: A Potential Game-Changer for NSCLC Treatment - TipRanks
AstraZeneca’s New Study on TDC Treatment for mNSCLC: Key Insights for Investors - TipRanks
Inside AstraZeneca’s long-term strategy in lung cancer - BioPharma Dive
Tempus AI (TEM) Q2 Revenue Surges 90% - The Motley Fool
Swedish Shares in North America – AstraZeneca Rises 1.1 Percent - MarketScreener
AstraZeneca’s Promising Phase II Study on AZD6234: A Potential Game-Changer for Type 2 Diabetes - TipRanks
AstraZeneca’s New COPD Study: Potential Market Shifts Ahead - TipRanks
Amgen and AstraZeneca’s HORIZON Study: A New Hope for Pediatric Asthma - TipRanks
AstraZeneca’s AZD9592 Study: A New Hope for Advanced Solid Tumors - TipRanks
AstraZeneca’s New Study on AZD5004: Potential Market Implications - TipRanks
AstraZeneca’s Phase III Study on Advanced Liver Cancer: Key Insights for Investors - TipRanks
AstraZeneca’s Promising Study on Volrustomig for Mesothelioma: Key Insights for Investors - TipRanks
AstraZeneca’s TITANium Study: A New Hope for B-Cell Malignancies? - TipRanks
AstraZeneca’s New Phase III Study: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks
AstraZeneca’s Phase 1 Study on AZD9833: A New Hope for Advanced Breast Cancer - TipRanks
AstraZeneca’s MaesTTRo Study: Real-world Insights into ATTR Amyloidosis - TipRanks
AstraZeneca’s New Study on Saruparib: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks
AstraZeneca’s Study on ATTR PN in Russian CTS Patients: Key Insights for Investors - TipRanks
AstraZeneca’s COPD Study: Key Insights and Market Impact - TipRanks
AstraZeneca’s Phase I Study on AZD4954: A Potential Game-Changer in Cardiovascular Treatment - TipRanks
AstraZeneca’s Saruparib Study: Key Insights for Investors - TipRanks
AstraZeneca’s New Study Aims to Revolutionize COPD Care - TipRanks
AstraZeneca’s New Study on Trastuzumab Deruxtecan: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
AstraZeneca’s Myasthenia Gravis Study in China: Key Insights for Investors - TipRanks
AstraZeneca Advances NASH Research with New Clinical Study - TipRanks
September 26th Options Now Available For AstraZeneca (AZN) - Nasdaq
Cancer Vaccines Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - The Globe and Mail
Inside AstraZeneca’s long-game strategy in lung cancer - PharmaVoice
Ex-dividend day weighs heavily on the FTSE this week - Proactive Investors
AstraZeneca’s Olaparib Study: Promising Update for Ovarian Cancer Treatment - TipRanks
Collaborating to innovate: AstraZeneca's collaborations in mRNAs, antisense oligos and cell therapy - BioXconomy
AstraZeneca, Sanofi Fail to Escape Drugmaker Conspiracy Claims - Bloomberg Law News
AstraZeneca’s New Study on AZD6234: Implications for Renal Impairment Treatment - TipRanks
AstraZeneca’s Promising NASH Treatment Study: Key Insights for Investors - TipRanks
AstraZeneca’s New Trial: A Potential Breakthrough for Eosinophilic Diseases in Children - TipRanks
AstraZeneca’s Phase III Study: A Potential Game-Changer for CKD Treatment - TipRanks
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):